Vicore Pharma Holding AB

Vicore Pharma Holding AB(VCRE)の株式分析

$9.440

+0.289 (+3.06%)終値時点

Loading chart…
高値
9.740
始値
9.570
出来高加重平均価格
9.51
出来高
25.16K
時価総額
—
安値
9.340
売買代金
239.20K
EV/EBITDA(TTM)
0.00

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.

AI分析 of Vicore Pharma Holding AB (VCRE)

買い

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.

バリュエーション指標

Vicore Pharma Holding AB(VCRE)の現在の予想PERは0.00で、5年平均はです。

予想PER

5年平均 P/E
現在のP/E
0.00

予想EV/EBITDA

5年平均 EV/EBITDA
現在のEV/EBITDA
0.00

予想PSR

適正
5年平均 P/S
13.42
現在のP/S
5.78
割高
36.44
割安
-9.61

VCRE のよくある質問 — Alphio AI が回答

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める